MORF Morphic Holding Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MORF

Price (delayed)

$24.09

Market cap

$1.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.19

Enterprise value

$1.12B

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. ...

Highlights
The company's equity has surged by 98% YoY
MORF's debt has shrunk by 58% YoY and by 27% QoQ
Morphic Holding's quick ratio has surged by 87% YoY but it has decreased by 9% QoQ
The net income has dropped by 142% year-on-year and by 4.8% since the previous quarter
MORF's EPS has dropped by 111% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://morphictx.com
Peers: OGN

Key stats

What are the main financial stats of MORF
Market
Shares outstanding
49.74M
Market cap
$1.2B
Enterprise value
$1.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.6
Price to sales (P/S)
179.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
168.97
Earnings
Revenue
$6.66M
EBIT
-$135.45M
EBITDA
-$134.39M
Free cash flow
-$110.07M
Per share
EPS
-$3.19
Free cash flow per share
-$2.22
Book value per share
$15.09
Revenue per share
$0.13
TBVPS
$15.01
Balance sheet
Total assets
$743.6M
Total liabilities
$20.43M
Debt
$1.14M
Equity
$723.17M
Working capital
$718.8M
Liquidity
Debt to equity
0
Current ratio
38.25
Quick ratio
37.6
Net debt/EBITDA
0.55
Margins
EBITDA margin
-2,019.1%
Gross margin
100%
Net margin
-2,039.3%
Operating margin
-2,341.3%
Efficiency
Return on assets
-23.6%
Return on equity
-24.4%
Return on invested capital
-29.3%
Return on capital employed
-18.7%
Return on sales
-2,035%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MORF stock price

How has the Morphic Holding stock price performed over time
Intraday
2.95%
1 week
4.15%
1 month
19.26%
1 year
-9.4%
YTD
-9.94%
QTD
5.15%

Financial performance

How have Morphic Holding's revenue and profit performed over time
Revenue
$6.66M
Gross profit
$6.66M
Operating income
-$155.84M
Net income
-$135.74M
Gross margin
100%
Net margin
-2,039.3%
The operating income has plunged by 167% YoY and by 9% from the previous quarter
The net income has dropped by 142% year-on-year and by 4.8% since the previous quarter
The gross profit has plunged by 91% YoY and by 24% from the previous quarter
The revenue has plunged by 91% YoY and by 24% from the previous quarter

Growth

What is Morphic Holding's growth rate over time

Valuation

What is Morphic Holding stock price valuation
P/E
N/A
P/B
1.6
P/S
179.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
168.97
MORF's EPS has dropped by 111% year-on-year
The company's equity has surged by 98% YoY
MORF's P/B is 65% below its 5-year quarterly average of 4.4 and 45% below its last 4 quarters average of 2.8
MORF's P/S is 194% above its 5-year quarterly average of 59.3 and 43% above its last 4 quarters average of 121.4
The revenue has plunged by 91% YoY and by 24% from the previous quarter

Efficiency

How efficient is Morphic Holding business performance
The ROA has plunged by 71% YoY but it has grown by 11% from the previous quarter
The return on equity has dropped by 53% year-on-year but it is up by 12% since the previous quarter
MORF's return on sales is down by 37% since the previous quarter
MORF's ROIC is down by 31% YoY but it is up by 16% QoQ

Dividends

What is MORF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MORF.

Financial health

How did Morphic Holding financials performed over time
The total assets has surged by 91% year-on-year
Morphic Holding's quick ratio has surged by 87% YoY but it has decreased by 9% QoQ
MORF's debt is 100% lower than its equity
The company's debt to equity has shrunk by 100% YoY
The company's equity has surged by 98% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.